vs
MESA LABORATORIES INC（MLAB）与MP Materials Corp.（MP）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是MP Materials Corp.的1.2倍（$65.1M vs $52.7M），MP Materials Corp.净利率更高（17.9% vs 5.6%，领先12.3%），MESA LABORATORIES INC同比增速更快（3.6% vs -13.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $-109.3M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs 4.0%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
MP Materials Corp.是总部位于美国的稀土材料生产商，拥有并运营加利福尼亚州芒廷帕斯矿，这是西半球唯一在产的稀土开采及加工设施，所产核心材料可广泛应用于电动汽车、风力发电机、国防工业等多个关键领域。
MLAB vs MP — 直观对比
营收规模更大
MLAB
是对方的1.2倍
$52.7M
营收增速更快
MLAB
高出17.2%
-13.6%
净利率更高
MP
高出12.3%
5.6%
自由现金流更多
MLAB
多$127.3M
$-109.3M
两年增速更快
MLAB
近两年复合增速
4.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $52.7M |
| 净利润 | $3.6M | $9.4M |
| 毛利率 | 64.2% | — |
| 营业利润率 | 12.2% | -7.0% |
| 净利率 | 5.6% | 17.9% |
| 营收同比 | 3.6% | -13.6% |
| 净利润同比 | 316.6% | 142.2% |
| 每股收益（稀释后） | $0.65 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABMP
| Q4 25 | $65.1M | $52.7M | ||
| Q3 25 | $60.7M | $53.6M | ||
| Q2 25 | $59.5M | $57.4M | ||
| Q1 25 | $62.1M | $60.8M | ||
| Q4 24 | $62.8M | $61.0M | ||
| Q3 24 | $57.8M | $62.9M | ||
| Q2 24 | $58.2M | $31.3M | ||
| Q1 24 | $58.9M | $48.7M |
净利润MLABMP
| Q4 25 | $3.6M | $9.4M | ||
| Q3 25 | $2.5M | $-41.8M | ||
| Q2 25 | $4.7M | $-30.9M | ||
| Q1 25 | $-7.1M | $-22.6M | ||
| Q4 24 | $-1.7M | $-22.3M | ||
| Q3 24 | $3.4M | $-25.5M | ||
| Q2 24 | $3.4M | $-34.1M | ||
| Q1 24 | $-254.6M | $16.5M |
毛利率MLABMP
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
营业利润率MLABMP
| Q4 25 | 12.2% | -7.0% | ||
| Q3 25 | 7.8% | -125.2% | ||
| Q2 25 | 5.1% | -76.5% | ||
| Q1 25 | 2.4% | -57.2% | ||
| Q4 24 | 9.2% | -72.1% | ||
| Q3 24 | 6.1% | -62.8% | ||
| Q2 24 | 9.6% | -171.1% | ||
| Q1 24 | -460.6% | -66.6% |
净利率MLABMP
| Q4 25 | 5.6% | 17.9% | ||
| Q3 25 | 4.1% | -78.0% | ||
| Q2 25 | 8.0% | -53.8% | ||
| Q1 25 | -11.4% | -37.2% | ||
| Q4 24 | -2.7% | -36.6% | ||
| Q3 24 | 5.9% | -40.5% | ||
| Q2 24 | 5.8% | -108.9% | ||
| Q1 24 | -432.2% | 33.9% |
每股收益（稀释后）MLABMP
| Q4 25 | $0.65 | $0.07 | ||
| Q3 25 | $0.45 | $-0.24 | ||
| Q2 25 | $0.85 | $-0.19 | ||
| Q1 25 | $-1.30 | $-0.14 | ||
| Q4 24 | $-0.31 | $-0.12 | ||
| Q3 24 | $0.63 | $-0.16 | ||
| Q2 24 | $0.62 | $-0.21 | ||
| Q1 24 | $-47.26 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $1.2B |
| 总债务越低越好 | $68.4M | $998.7M |
| 股东权益账面价值 | $186.7M | $2.0B |
| 总资产 | $434.8M | $3.9B |
| 负债/权益比越低杠杆越低 | 0.37× | 0.50× |
8季度趋势，按日历期对齐
现金及短期投资MLABMP
| Q4 25 | $29.0M | $1.2B | ||
| Q3 25 | $20.4M | $1.1B | ||
| Q2 25 | $21.3M | $261.5M | ||
| Q1 25 | $27.3M | $198.3M | ||
| Q4 24 | $27.3M | $282.4M | ||
| Q3 24 | $24.3M | $284.4M | ||
| Q2 24 | $28.5M | $295.6M | ||
| Q1 24 | $28.2M | $296.5M |
总债务MLABMP
| Q4 25 | $68.4M | $998.7M | ||
| Q3 25 | $69.4M | $997.3M | ||
| Q2 25 | $70.3M | $910.8M | ||
| Q1 25 | $71.3M | $909.8M | ||
| Q4 24 | $72.2M | $908.7M | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABMP
| Q4 25 | $186.7M | $2.0B | ||
| Q3 25 | $178.5M | $2.0B | ||
| Q2 25 | $172.5M | $1.0B | ||
| Q1 25 | $159.8M | $1.0B | ||
| Q4 24 | $155.2M | $1.1B | ||
| Q3 24 | $161.5M | $1.1B | ||
| Q2 24 | $150.7M | $1.1B | ||
| Q1 24 | $145.4M | $1.1B |
总资产MLABMP
| Q4 25 | $434.8M | $3.9B | ||
| Q3 25 | $430.4M | $3.8B | ||
| Q2 25 | $435.7M | $2.3B | ||
| Q1 25 | $433.3M | $2.4B | ||
| Q4 24 | $433.3M | $2.3B | ||
| Q3 24 | $454.1M | $2.3B | ||
| Q2 24 | $440.4M | $2.4B | ||
| Q1 24 | $446.8M | $2.4B |
负债/权益比MLABMP
| Q4 25 | 0.37× | 0.50× | ||
| Q3 25 | 0.39× | 0.51× | ||
| Q2 25 | 0.41× | 0.90× | ||
| Q1 25 | 0.45× | 0.88× | ||
| Q4 24 | 0.47× | 0.86× | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $-46.9M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $-109.3M |
| 自由现金流率自由现金流/营收 | 27.7% | -207.4% |
| 资本支出强度资本支出/营收 | 1.1% | 118.5% |
| 现金转化率经营现金流/净利润 | 5.17× | -4.97× |
| 过去12个月自由现金流最近4个季度 | $37.9M | $-328.1M |
8季度趋势，按日历期对齐
经营现金流MLABMP
| Q4 25 | $18.8M | $-46.9M | ||
| Q3 25 | $8.2M | $-42.0M | ||
| Q2 25 | $1.9M | $-3.7M | ||
| Q1 25 | $12.7M | $-63.2M | ||
| Q4 24 | $18.1M | $30.5M | ||
| Q3 24 | $5.3M | $-6.8M | ||
| Q2 24 | $10.7M | $30.8M | ||
| Q1 24 | $12.9M | $-41.1M |
自由现金流MLABMP
| Q4 25 | $18.0M | $-109.3M | ||
| Q3 25 | $7.1M | $-92.5M | ||
| Q2 25 | $884.0K | $-32.7M | ||
| Q1 25 | $11.9M | $-93.7M | ||
| Q4 24 | $17.3M | $-11.2M | ||
| Q3 24 | $3.5M | $-53.3M | ||
| Q2 24 | $9.9M | $-15.6M | ||
| Q1 24 | $12.3M | $-93.0M |
自由现金流率MLABMP
| Q4 25 | 27.7% | -207.4% | ||
| Q3 25 | 11.7% | -172.8% | ||
| Q2 25 | 1.5% | -56.9% | ||
| Q1 25 | 19.2% | -154.0% | ||
| Q4 24 | 27.6% | -18.3% | ||
| Q3 24 | 6.0% | -84.7% | ||
| Q2 24 | 16.9% | -50.1% | ||
| Q1 24 | 21.0% | -191.0% |
资本支出强度MLABMP
| Q4 25 | 1.1% | 118.5% | ||
| Q3 25 | 1.8% | 94.3% | ||
| Q2 25 | 1.7% | 50.5% | ||
| Q1 25 | 1.2% | 50.1% | ||
| Q4 24 | 1.3% | 68.3% | ||
| Q3 24 | 3.1% | 73.8% | ||
| Q2 24 | 1.5% | 148.7% | ||
| Q1 24 | 0.9% | 106.5% |
现金转化率MLABMP
| Q4 25 | 5.17× | -4.97× | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | -2.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
MP
| Materials Segment | $35.6M | 68% |
| Other | $17.1M | 32% |
